

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	January 1, 2026

Bonsity® (teriparatide)/Forteo® (teriparatide) Injection

LENGTH OF AUTHORIZATION: UP TO ONE YEAR

REVIEW CRITERIA:

For the treatment of postmenopausal women with osteoporosis at high risk for fracture; or increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture; or treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy at high risk for fracture:

INITIATION OF THERAPY

- Patient must be ≥ 18 years old; **AND**
- Prescribed by or in consultation with a specialist (endocrinologist, rheumatologist, or obstetrician/gynecologist); **AND**
- The patient is taking calcium and vitamin D (*Must be confirmed in medical records or pharmacy claims*); **AND**
- Documented diagnosis of osteoporosis with A DXA hip (femoral neck) or spine T-score ≤ -2.5 (dated within the past 2 years). (*Must be confirmed in medical records.*); **OR**
- History of a fracture of the spine or hip. (*Must be confirmed in medical records.*); **OR**
- History of T-score between -1.0 and -2.5 if FRAX (WHO Fracture Risk Assessment Tool) major osteoporotic fracture probability is $\geq 20\%$ or hip fracture probability is 3%. (*Must be confirmed in medical records.*); **AND**
- Trial (minimum of 12 months) and failure of zoledronate (documentation required):
 - Failure may be defined as an intolerance (adverse reaction, contraindication...) to other bisphosphonates, or no increase from baseline bone mineral density (BMD) as indicated by T-score history, or recurring fractures (in the absence of major trauma) following at least one year of therapy.

CONTINUATION OF THERAPY

- The patient is taking calcium and vitamin D (*Must be confirmed in medical records or pharmacy claims*); **AND**
- If request is for continuation of cumulative therapy beyond 2 years, provider must attest that member remains at or has returned to having a high risk for fracture; **AND**
- Medical records must demonstrate a stable BMD (within interventional goals) or an increasing BMD after a minimum trial of one year of therapy.
 - T-score test results may date back as far as five years.
 - Depending on level of BMD progression retesting may be done from every one to five years.
 - Medical records should demonstrate improvement by providing reference to the sequential progression or stability of the BMD.

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	January 1, 2026

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>